CML-CP: Imatinib at higher dose or in combination with other drugs offers no survival benefitMarch 15, 2021CML
Dr. Pinilla-Ibarz: Trial supports the use of nilotinib 300mg twice daily as front line therapy for CML February 10, 2021CML
Patients with CML at higher risk for adverse cardiovascular events in the TKI era February 10, 2021CML
High LDL increases arterial occlusive events risk in CML patients treated with nilotinibFebruary 10, 2021CML
